Replimune Group (REPL) analyst forecast and price target
Analyst forecast
Consensus of 8 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| JP Morgan | Maintained | Overweight | $21.00 from $20.00 | Aug 26, 2026 |
| Wedbush | Upgraded | Neutral → Outperform | $19.00 from $12.00 | Aug 7, 2026 |
| JP Morgan | Maintained | Overweight | $20.00 from $17.00 | Aug 7, 2026 |
| Leerink Partners | Upgraded | Market Perform → Outperform | $17.00 from $11.00 | Aug 4, 2026 |
| Cantor Fitzgerald | Upgraded | Neutral → Overweight | — | Jul 31, 2026 |
| Wedbush | Maintained | Neutral | $12.00 from $9.00 | Jul 31, 2026 |
| Wedbush | Maintained | Neutral | $9.00 from $6.00 | Jun 30, 2026 |
| Wedbush | Maintained | Neutral | $6.00 from $2.00 | Jun 1, 2026 |
| HC Wainwright & Co. | Downgraded | Buy → Sell | — | Apr 13, 2026 |
| Jefferies | Downgraded | Buy → Hold | $2.00 from $13.00 | Apr 13, 2026 |
| Wedbush | Downgraded | Outperform → Neutral | $2.00 from $19.00 | Apr 13, 2026 |
| JP Morgan | Downgraded | Neutral → Underweight | — | Apr 13, 2026 |
| Leerink Partners | Downgraded | Outperform → Market Perform | $2.00 from $11.00 | Apr 13, 2026 |
| Cantor Fitzgerald | Downgraded | Overweight → Neutral | — | Apr 13, 2026 |
| Piper Sandler | Maintained | Overweight | $14.00 from $13.00 | Feb 5, 2026 |
| Wedbush | Maintained | Outperform | $19.00 from $18.00 | Feb 4, 2026 |
| BMO Capital | Upgraded | Underperform → Market Perform | $11.00 from $2.00 | Nov 3, 2025 |
| HC Wainwright & Co. | Upgraded | Neutral → Buy | $12.00 | Oct 27, 2025 |
| Wedbush | Upgraded | Neutral → Outperform | $18.00 from $4.00 | Oct 20, 2025 |
| Leerink Partners | Upgraded | Market Perform → Outperform | $13.00 from $3.00 | Oct 20, 2025 |
Frequently asked questions
What is the price target for REPL stock?
The average 12-month analyst price target for Replimune Group (REPL) is $19.00, with a high estimate of $21.00 and a low of $17.00, across 3 analysts.
Is REPL a buy, sell, or hold?
Analysts covering Replimune Group currently average a Buy rating: 8 buy, 0 hold and 0 sell, from 8 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for REPL?
The average price target of $19.00 implies 66.81% upside from the last price of $11.39.
What is the latest analyst rating on REPL?
On Aug 26, 2026, JP Morgan maintained Replimune Group at Overweight with a price target of $21.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.